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Objectives: We aimed to (1) describe the real-world treatment of UTIs in a T2DM 
population, (2) investigate UTI related healthcare resource use, (3) assess treat-
ment costs associated with UTI, and (4) identify factors which may predict UTI-
related treatment costs. MethOds: We analysed an anonymized dataset from a 
regional German healthcare fund (AOK PLUS) including all continuously insured 
T2DM-prevalent patients from 2010-2012. Health care resource use was reported 
per UTI episode. A UTI episode was identified through coded outpatient/inpatient 
UTI diagnoses (ICD-10 N39.0) and, in case of recurrent diagnoses, prescribed anti-
biotics for UTI treatment. Results: A total of 456,586 T2DM patients (mean age of 
73.8 years, 56.3% female, mean CCI of 7.3, mean observational period of 665.5 days) 
was included. We identified 48,337 UTI episodes. During an observed UTI episode, 
patients visited with a median/mean of 1.0/0.8 times a GP and 0.0/0.3 times an 
urologist. In 6.7% of the cases, an inpatient treatment was caused by a UTI with a 
median/mean length of stay of 7.0/8.7 days. In 74.8% of the observed UTI episodes, 
antibiotics labelled for this disease were prescribed (mean prescribed DDD 10.5 
days). Mean/median costs directly associated with UTI treatment (bottom-up costs) 
were 315.90€ /102.28€ per UTI episode. Factors significantly increasing UTI-related 
direct bottom costs were age, female gender, worse CKD status (5/5), CCI, and at 
least one previous UTI infection in the reference period. In an additional top-down 
cost analysis, annual all-cause cost per patient year were 5,519 € higher in the UTI 
group compared to T2DM patients not having experienced an UTI. This translated 
into a UTI-related marginal cost-increasing effect of 3,916€ per patient year in a 
multivariable Gamma regression analysis. cOnclusiOns: Given that worldwide 
increasing prevalence of T2DM, the incidence of UTI infection in T2DM represents 
substantial resource use/cost burden for healthcare systems.
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Objectives: There is limited real-world information on resource utilisation, costs 
and productivity in patients with ADPKD. The objective of this study was to esti-
mate the annual direct and indirect costs of patients with ADPKD by severity of the 
disease [chronic kidney disease (CKD) stages 1–3, 4–5, dialysis, and transplant recipi-
ents], and describe the resource utilisation during the 12-month period around dial-
ysis initiation and transplant procedure, respectively. MethOds: A cross-sectional 
study of ADPKD patients was undertaken April–December 2014 in Denmark, Finland, 
Norway and Sweden. Data on medical resource utilisation were extracted from med-
ical charts and patients were asked to complete a self-administered survey, which 
included the Work Productivity and Activity Impairment Questionnaire. Results: A 
total of 266 patients were contacted, 243 (91%) of whom provided consent to partici-
pate in the study. Average total annual costs amounted to € 9,919 in CKD 1–3, € 16,761 
in CKD 4–5, € 74,015 in dialysis patients and € 31,496 in transplant recipients. Indirect 
costs were substantial in earlier stages of the disease, accounting for 72% and 73% 
of total costs in the CKD 1–3 and CKD 4–5 strata, respectively. Direct medical costs 
amounted to € 60,514 in dialysis patients and € 17,773 in transplant recipients. Among 
those who were employed, the overall work productivity loss ranged between 9% 
in CKD stage 1–3 to 42% in dialysis patients. An average of 16.5 hospital days and 
10.4 outpatient visits were observed in the 12-month period around dialysis initia-
tion. Around the transplant procedure, the average number of hospital days and 
outpatient visits were 29.9 and 16.9, respectively. cOnclusiOns: ADPKD is a pro-
gressive disease associated with increasing costs as the patient progresses to CKD 
stage 4–5, dialysis and transplant. Substantial savings and productivity gains could 
be made by delaying the progression of ADPKD to end stage renal disease.
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Objectives: Aim of the present study was to evaluate, through the analysis of 
administrative databases, healthcare resource consumption and costs in charge 
to the Regional Health Service (RHS) for patients receiving kidney transplanta-
tion. MethOds: All data recorded in the regional administrative databases regard-
ing subjects resident in Lombardy (one of the Italian Regions, with about 9,700,000 
inhabitants) who received kidney transplantation in 2011 were extracted. Direct 
healthcare costs in charge to the RHS for these subjects for the 12 months preced-
ing and following transplantation were estimated (drugs, hospitalizations, diag-
nostic/therapeutic procedures). Results: In 2011, 276 subjects received kidney 
transplantation, 268 of which survived for the following 12 months. Administrative 
data were available for 264 of these subjects (67.8% males, mean age 49.4). Among 
those patients who survived one year after transplantation, the per-patient yearly 
cost before transplantation amounted to 36,746€ (11.6% for drugs, 81.2% for diag-
nostic/therapeutic procedures and 7.2% for hospitalizations). Dialysis accounted 
for 91% of all costs for diagnostic/therapeutic procedures. In the year following 
transplantation, the per-patient cost amounted to 43,806€ (25.8% for drugs, 15.8% 
for diagnostic/therapeutic procedures and 58.4% for hospitalizations). The average 
per-patient cost of transplantation intervention was 21,183€ (82.7% of total cost 
of hospitalizations). The average cost of the last year of life of those patients who 
died within 12 months after transplantation was 79,362€ /patient (68.1% of which 
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Objectives: Chronic kidney disease (CKD) has become a major public health 
problem in China. Two sample cities, Qingdao, which has been providing out-
patient service with CKD patients in non-dialysis phases, and Shenyang, which 
has not provided the service, are selected as samples to discuss the policy effect 
of out-patient medical insurance. MethOds: CKD patient data collected in medi-
cal insurance administrative agencies of two sample cities in 2009 and 2010 are 
analyzed through discriptive statistics and independent sample T-test. Results: 
1) For kidney dialysis (KD) patients, out-patient growth rates of Qingdao and 
Shenyang are 8.15% and 15.93% respectively, and average ages are 56.14 and 
57.67 (P= 0.516); in-patient growth rates of Qingdao and Shenyang are -5.28% and 
16.01% respectively, and average ages are 60.56 and 58.88 (p= 0.000). 2) For renal 
transplantated (RT) recipients, out-patient growth rates of Qingdao and Shenyang 
are 7.80% and 8.15% respectively, and average ages are 48.71 and 48.73 (p= 0.172); 
in-patient growth rates of Qingdao and Shenyang are -6.98% and 2.65% respec-
tively, and average ages are 46.79 and 50.44 (p= 0.000). 3) On medical insurance 
fund expenditure, expenditure growth rates of KD out-patients and in-patients 
of Qingdao are -4.80% and -11.59% respectively, and those of Shenyang are 22.51% 
and 36.52%; expenditure growth rates of out-patient and in-patient RT recipients 
of Qingdao are -5.50% and -25.60% respectively, and those of Shenyang are 6.48% 
and -3.79%. cOnclusiOns: 1) Out-patient insurance creates a positive effect on 
controlling the excessive growth of the number of KD patients, while the effect 
is not so significant on the number of RT recipients. 2) Out-patient insurance 
produces effective results on controlling the rapid growth of medical insurance 
fund expenditure scale of KD patients, while the effect is not so significant of RT 
recipients. 3) Average ages of KD patients have not been decreased effectively 
because of the short period of policy implementation.
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Objectives: The objective of this study was to establish current practice in TDM 
in K-Tx in a real-world clinical setting, and to develop a best-practice concept to 
improve patient care. MethOds: TDM processes for transplanted patients were col-
lected at 13 centers in 5 countries between January 2015 and June 2015. More than 35 
Interviews with physicians, nurses and lab assistants were combined with observa-
tion of relevant steps during standard examination sessions. Duration of each main 
step to adjust the patient medication dose was recorded. Also dependencies from 
outside variables were recorded. Results: Several process patterns were identified. 
Main observed differences among centers were process steps and inefficiencies in 
exam setup and time required getting test results. The time gap between taking blood 
samples and availability of results leads to long patient stay and/or multiple visits or 
contacts with the patient (blood test, examination, result communication). Average 
time for patients in a center was 2:12 hours with a large range from 0:49 hours to 
6:22 hours. Process time for blood drawing, examinations and results communica-
tion (excluding lab processing) was on average 30 min ranging from 12 min to 52 
min. Complexity and time to get the results could be improved if a near-patient-test 
(NPT) scenario would be available while others are subject to normal process improve-
ments. cOnclusiOns: Results suggest that improvements could be made in all types 
of scenarios. Especially fast availability of test results in a NPT scenario could reduce 
complexity and facilitate the development of an improved process setup.
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Objectives: The aim of our study is to analyse the biosimilar bids of the Hungarian 
National Health Insurance Fund Administration in case of erythropoietin (ESA) prod-
ucts. MethOds: Data derived from the nationwide pharmaceutical database of 
Hungarian National Health Insurance Fund Administration. We analysed how the 
number of patients treated by erythropoietin products changed before (01.07.2011.-
30.06.2012.) and after (01.07.2012.-30.06.2013.) the first biosimilar bid performed 
in March 2012 in Hungary. Results: In the 12 months before biosimilar bid 4,482 
patients received erythropoietin treatment, while in the first 12 months after the bid 
4,545 patients, resulting in a 1.4 % increase. The second 12 months after the bid 4,644 
patients received erythropoietin treatment, resulting in a 3.6 % increase. Before the 
biosimilar bid, the NHIFA spent 2.33 billion Hungarian Forint (HUF) health insurance 
reimbursement for ESA products, which decreased by 47 % to 1.23 billion HUF in the 
first year after biosimilar bid. cOnclusiOns: The analyses of the Hungarian price 
competition bid of biosimilar products showed a minimal decline in the number of 
patients under treatment by erythropoietin products while the health insurance 
reimbursement of these drugs significantly decreased.
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articles; corporate, foundation and government reports; and existing literature 
reviews. Results: Preliminary results demonstrate a growing recognition within 
the industry of the value of understanding patient experiences and perspectives. 
Patient involvement in research varies tremendously, from superficial and token-
istic to highly substantive (e.g., patient involvement in every stage of the research 
process, from framing research questions to dissemination of results). Research 
on the outcomes of patient involvement is largely qualitative, making it difficult 
to arrive at generalizable conclusions. Positive results often are assumed without 
being empirically demonstrated. That said, the literature suggests patient involve-
ment can lead to benefits for all stakeholders, including increased legitimacy and 
transparency, better alignment of research agendas with outcomes that patients 
value, higher data quality and better communication of results to lay audiences. 
Other sources, however, highlight barriers to incorporating a patient-centered 
perspective, such as resistance to diverting research resources, defensiveness 
relating to researchers’ expertise and traditional practices and the time and effort 
necessary to include patients in an already lengthy R&D process. cOnclusiOns: 
While there is a growing literature on patient involvement in industry research, the 
current lack of robust evidence on the outcomes of patient involvement hinders 
effective inclusion of patients. Further development of a science of patient involve-
ment is a necessary step for broadening and strengthening industry inclusion of 
patients in the drug development process.
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Objectives: The aim of the paper is to analyze the needs and attitude of elderly 
people towards technology, as a prelude for designing and testing new healthcare 
and assistance services. MethOds: Focus groups and questionnaires administered 
in Tuscany (Italy) to a) over 65 resident in their home, living alone, with no cognitive 
impediments; b) formal and c) informal caregivers. Results: What the elderly need 
can be summarized into indoor and outdoor safety and protection services. According 
to the elderly people the preferred solution to meet these needs is a mix of: increas-
ing frequency of contacts with caregivers, maintaining social relations, improving 
their indoor autonomy. On these premises 72% of the interviewed sample would be 
interested in using telemedicine platform for monitoring their health conditions; 
73.5% would improve their house safety by using technology; 53% would adopt ICT 
technology and sensors to monitor their home when they are in or out. 47% would 
adopt tele-gym for making simple exercises everyday. 68% believes that a video-
call system could be an useful solution to keep in touch with relatives and friends.
These answers are related to a population characterized by 71% of under 75 and 85% 
of over 75 with some disease; 10% of over 75 citizens is not self-sufficient; 32% of 
under 75 and 73% of over 75 citizens receive a concrete help by formal and informal 
caregivers. cOnclusiOns: Results show a high interest of the elderly people in ser-
vices delivered with ICT technology and sensors for supporting their daily activities, 
improving safety and reducing the related healthcare resource consumption.
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Objectives: In order to improve pharmaceutical care delivery in Malaysia, Ministry 
of Health introduced the concept of Value Added Services (VAS) in pharmacy. Despite 
the reported convenience and advantages of VAS, it is noticed that utilization rate of 
VAS is low in the country. The study aims to explore patients’ understanding, sali-
ent beliefs and expectations towards VAS in Malaysia using the Theory of Planned 
Behaviour (TPB) as a theoretical model. MethOds: A qualitative methodology was 
used whereby face-to-face interviews were conducted with 12 patients who collected 
partial medicine supplies from government pharmacies. Participants were recruited 
using purposive and snowball sampling method in the State of Negeri Sembilan, 
Malaysia. Interviews were audio-recorded. Verbatim transcription and thematic 
content analysis were performed on the data. Results: Thematic content analysis 
yielded five major themes. (1) Attitudes towards using VAS, (2) subjective norms, (3) 
perceived behavioural control, (4) lack of knowledge and understanding of VAS and (5) 
expectations toward VAS. cOnclusiOns: The interviews explored and informed new 
information about salient beliefs towards pharmacy VAS in Negeri Sembilan, Malaysia. 
The findings suggest that VAS is still in its infancy and a more robust and effective 
advertising and marketing campaign is needed to boost the adoption rate. Behavioural 
attitudes, subjective norms and perceived control elements were discussed and serve 
as important variables of interest in future study. Expectations towards VAS serve as 
an important guideline to further improve patient-oriented services.
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Objectives: To analyze health services utilization among elderly in 
Slovenia. MethOds: Health services utilization among elderly depends on many 
factors. However, it is important to realize that older people in their consumption 
of health care services are not a homogeneous group as they may be particularly 
exposed to personal income and social inequalities. To better understand the fac-
tors that influence the use of health care resources among the elderly in Slovenia, 
we used a database of Wave 4 of the Survey of Health, Ageing and Retirement in 
Europe (SHARE). The SHARE data were self-reported and included indicators of 
health services utilization, such as the number of contacts with general practition-
for hospitalizations). cOnclusiOns: Kidney transplantation substantially changes 
the composition of costs associated to patients affected by end stage renal disease, 
dramatically reducing the costs of diagnostic/therapeutic procedures and increas-
ing drug expenditure. When evaluating the increase in hospitalization costs, the 
incidence of transplantation expenditure should be considered. Speculatively, it 
should be expected that in the following years the per-patient cost would decrease 
thanks to savings following the reduction in dialysis costs.
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Objectives: To evaluate the impact of anaemia on healthcare resource utilisa-
tion and work productivity in patients with chronic kidney disease (CKD) stages 3 
and 4, and patients on dialysis. MethOds: A descriptive, cross-sectional analysis 
was performed using data from the Adelphi CKD Disease Specific Programme in 
France, Germany, Italy, Spain, and UK between June and September 2012. Healthcare 
resource utilisation data was extracted from patient self-completion questionnaires 
and physician-completed patient record forms. Absenteeism and work-related 
activity impairment data were obtained from the Work Productivity and Activity 
Impairment questionnaire. Results: A total of 1336 patient self-completed ques-
tionnaires were received from an evaluable population of 2898 CKD patients (stage 
3, 4, and on dialysis). Across all patient sub-groups, anaemic patients accrued more 
nephrologist visits over 12 months, compared to non-anaemic patients (2.7 vs. 1.1). 
Anaemic patients also experienced a higher number of visits to a general practi-
tioner (3.5 vs. 2.9). Stratification of the data, by haemoglobin (Hb) level and dialysis 
status, revealed that the number of all-cause hospitalisations was consistently 
higher for patients with Hb levels of < 10 g/dL, compared to those with Hb levels of 
≥ 12 g/dL, irrespective of dialysis treatment (0.7 vs. 0.2 and 0.9 vs. 0.5 admissions for 
non-dialysis and dialysis subjects, respectively). Anaemic CKD stage 4 and dialysis 
patients < 65 years, had higher rates of work absenteeism compared with non-
anaemic patients (3.6% vs. 2.4% stage 4 and 14.6% vs. 7.6% dialysis). Anaemia caused 
greater activity impairment (whilst working) among CKD stage 3 patients (23.6% 
anaemic vs. 14.7%) and stage 4 patients (26.4% anaemic vs. 20.0%), compared with 
dialysis patients (37.2% anaemic vs. 44.6%). cOnclusiOns: Anaemia may have 
a substantial impact on healthcare resource utilisation and work productivity in 
patients with CKD. Further studies are warranted to evaluate the humanistic impact 
and direct economic burden of anaemia in CKD.
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Objectives: Determine the health impact through an economic evaluation in rela-
tion to expenditure and quality of care for patients with chronic kidney disease 
(CKD) on hemodialysis two insurers and their network of providers between 2013 
and 2014. MethOds: The information system containing data tracking high-cost 
diseases in the Colombian health system, an economic tool was generated with the 
methodological parameters recommended by WHO to assess populations with CKD 
stage 5: 22926 patients (2013) and 23478 (2014), which were selected on hemodialy-
sis 1043/16029 (6.51%) and 1673/16334 (10.24%) respectively. The analysis included 
comparisons of clinical outcomes, cost-effectiveness ratio (CER) and incremental 
cost effectiveness ratio (ICER) between 5 providers and 58 renal units. Results: 
Comparing scenarios 2 insurance providers found that in RCE there is a difference 
range from US$ 3.272,28 to US$ 4.586,69 patient year (2013) and from US$ 10,93 to 
US$ 3.980,30 patient year (2014). The ICER was cost-saving scenarios in a difference 
of US$ 22.880,00 (2013) and US$ 69.733,80 (2014) and in non-cost effective differ-
ence per patient year it was US$ 158.145,07 (2013) and the actual cost difference 
per patient year was US$ 3.960,00 (2014). Additionally it was noted that the insur-
ance1 vs. insurance2 was saving the cost and RCE had a difference of US$ 1.086,54 
per patient year (2013), then noted that insurance1 vs. the insurance2 proved to 
be highly cost effective and RCE had a difference of US$ 2.340,04 per patient year 
(2014). cOnclusiOns: 1) To support the evaluation of healthcare programs that hire 
insurance, 2) Complement health evaluation results through the economic evalua-
tion of health care programs and 3) Identify what kind of joint venture agreement 
may be useful for the management of high-cost diseases.
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Objectives: To better understand the views of various stakeholders on patient 
involvement in pharmaceutical industry research and to describe the current 
state of knowledge of best practices. MethOds: A targeted review of the lit-
erature on patient involvement with pharmaceutical drug development and 
research. Approximately 150 articles were reviewed, including academic journal 
